Drugs / Articaine
Articaine
also known as
articaine hydrochloride · AG-920 · Articaine HCl · Septocaine · 40 045 · Articaina · Articaine chloride · Articaine hydrochloride component of orabloc · +10 more
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | SEPTOCAINE | — | 2000-04-03 | fda.gov ↗ |
Trials 51 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04171349 | Jun → Oct 2019 | kidney failure | Ain Shams University | Completed | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT06564987 | Jan → Dec 2024 overdue | — | Cleveland Dental Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT04759339 | Feb 2021 | — | American Genomics, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04189198 | Dec 2019 → Mar 2020 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05585112 | Oct → Dec 2022 | — | Latakia University | Completed | No outcome recorded |
| Phase 1/2 | NCT05200884 | Jan → Mar 2022 | — | Latakia University | Completed | No outcome recorded |
| Phase 1/2 | NCT04061265 | Aug 2019 → Jan 2020 | — | Minia University | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05840913 | Dec 2023 → Jul 2024 | pulpitis | Armed Forces Institute of Dentistry, Pakistan | Completed | No outcome recorded |
| Phase 2 | NCT06862570 | Dec 2022 → May 2023 | pulpitis | 28 Military Dental Centre Lahore | Completed | No outcome recorded |
| Phase 2 | NCT05223075 | Nov 2022 → Feb 2023 | — | Fayoum University | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03725579 | Sep → Dec 2018 | pulpitis | Cairo University | Unknown | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT05839548 | Jul 2023 → May 2025 overdue | dental caries, dental pulp disorder | Qassim Health Cluster | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05501860 | Jul → Dec 2022 | — | American Genomics, LLC | Completed | No outcome recorded |
| Phase 3 | NCT05325853 | Apr → May 2022 | — | American Genomics, LLC | Completed | No outcome recorded |
| Phase 3 | NCT04477317 | Aug → Sep 2021 | — | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT04829344 | Mar → May 2021 | — | American Genomics, LLC | Completed | No outcome recorded |
| Phase 3 | NCT04513652 | Sep 2020 | — | American Genomics, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02807298 | Jun → Oct 2014 | pulpitis | Dr. D. Y. Patil Dental College & Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00332735 | May 2006 → Jan 2007 | — | Reinier de Graaf Groep | Completed | No outcome recorded |
| Phase 3 | NCT00247741 | Nov 2005 → May 2006 | — | St. Antonius Hospital | Completed | No outcome recorded |
| Phase 418 trials | ||||||
| Phase 4 | NCT07231614 | Dec 2025 overdue | — | Universidad Austral de Chile | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06161714 | Nov 2023 → Apr 2024 | — | Riyadh Elm University | Unknown | No outcome recorded |
| Phase 4 | NCT03318952 | Sep 2022 → Jun 2023 | — | Boston University | Withdrawn | No outcome recorded |
| Phase 4 | NCT05443009 | Jun 2022 → Jul 2024 | dental pulp disorder | Universidade Federal de Santa Catarina | Completed | No outcome recorded |
| Phase 4 | NCT04186299 | Aug 2021 → Aug 2022 | pulpitis | University of California, San Francisco | Withdrawn | No outcome recorded |
| Phase 4 | NCT05252117 | Feb 2021 → Apr 2022 | — | Universidade do Vale do Sapucai | Unknown | No outcome recorded |
| Phase 4 | NCT04166890 | Sep 2018 → Jan 2020 | — | Universidad de Antioquia | Completed | No outcome recorded |
| Phase 4 | NCT03354312 | Dec 2017 → Nov 2018 | periodontitis | Chemische Fabrik Kreussler & CO GmbH | Completed | No outcome recorded |
| Phase 4 | NCT03470532 | Feb 2017 → Mar 2018 | — | Melaka Manipal Medical College | Completed | No outcome recorded |
| Phase 4 | NCT03225326 | Dec 2016 → Jun 2017 | — | University of Belgrade | Withdrawn | No outcome recorded |
| Phase 4 | NCT03279757 | Oct → Dec 2016 | — | Netherlands Institute for Pigment Disorders | Completed | No outcome recorded |
| Phase 4 | NCT02938286 | Mar → Aug 2016 | — | Netherlands Institute for Pigment Disorders | Completed | No outcome recorded |
| Phase 4 | NCT02548533 | Jun 2015 → Jan 2016 | — | Netherlands Institute for Pigment Disorders | Terminated | No outcome recorded |
| Phase 4 | NCT02105090 | Oct 2014 → Dec 2019 | dyspepsia, esophageal varices with bleeding | Helsinki University Central Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02246179 | Sep → Oct 2014 | — | Netherlands Institute for Pigment Disorders | Completed | No outcome recorded |
| Phase 4 | NCT02457325 | Jun 2011 → Dec 2012 | impacted teeth, multiple, local anesthetic poisoning | University of Sao Paulo | Completed | No outcome recorded |
| Phase 4 | NCT02054767 | Aug 2010 → Nov 2012 | — | University of Sao Paulo | Completed | No outcome recorded |
| Phase 4 | NCT01912755 | Feb → Nov 2010 | pulpitis | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase not applicable13 trials | ||||||
| — | NCT07608900 | Aug 2026 → Aug 2027 expected | — | TC Erciyes University | Not yet recruiting | No outcome recorded |
| — | NCT07604337 | Jun → Dec 2026 expected | delirium | seher orbay yasli | Not yet recruiting | No outcome recorded |
| — | NCT07145879 | Jan → Jul 2025 | hemorrhagic disease, neuropathy, painful | Pamukkale University | Completed | No outcome recorded |
| — | NCT06423859 | Feb → Aug 2024 | — | Benha University | Unknown | No outcome recorded |
| — | NCT06119139 | Dec 2023 → Dec 2024 | pulpitis | Cairo University | Unknown | No outcome recorded |
| — | NCT05944341 | Jun → Jul 2023 | dental pulp disorder | Minia University | Unknown | No outcome recorded |
| — | NCT05473819 | May → Jun 2022 | — | Alexandria University | Unknown | No outcome recorded |
| — | NCT05238727 | Mar 2022 → Mar 2023 | pulpitis | Cairo University | Unknown | No outcome recorded |
| — | NCT05728151 | Feb 2022 → Apr 2024 | strabismus | Research Institute of Ophthalmology, Egypt | Completed | No outcome recorded |
| — | NCT05101785 | Nov 2021 → Sep 2022 | — | Mahmoud Ahmed Mahmoud | Unknown | No outcome recorded |
| — | NCT03942991 | Sep → Nov 2019 | — | Cairo University | Unknown | No outcome recorded |
| — | NCT05239078 | Mar 2016 → Feb 2017 | pulpitis | Dr. Vivek Aggarwal | Completed | No outcome recorded |
| — | NCT02422823 | Apr 2015 → Jun 2016 | pulpitis | Isabel Peixoto Tortamano | Completed | No outcome recorded |
Also used as a comparator or background therapy in 28 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03612323 Comparator | Nov 2018 → May 2019 | pulpitis | Cairo University | Unknown | No outcome recorded |
| Phase 0 | NCT05614440 Background | May 2012 → Nov 2013 | — | Marmara University | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT06980363 Comparator | Jun → Aug 2025 overdue | — | Fayoum University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT03880409 Comparator | Feb → Sep 2019 | — | Taibah University | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06538233 Comparator | Jan → Oct 2024 overdue | — | Cleveland Dental Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT04104789 Comparator | Sep 2020 → Sep 2021 | dental caries, periodontitis | Virginia Commonwealth University | Withdrawn | No outcome recorded |
| Phase 2 | NCT04105985 Comparator | Aug 2020 → Aug 2021 | dental caries, periapical periodontitis | Virginia Commonwealth University | Withdrawn | No outcome recorded |
| Phase 2 | NCT03962634 Comparator | Aug → Sep 2019 | dental caries, periodontitis | Virginia Commonwealth University | Terminated | No outcome recorded |
| Phase 48 trials | ||||||
| Phase 4 | NCT05908305 Comparator | Jun → Sep 2023 | opiate dependence, tooth disorder | University of Algiers | Unknown | No outcome recorded |
| Phase 4 | NCT04236115 Comparator | Sep 2017 → Apr 2018 | — | Taibah University | Completed | No outcome recorded |
| Phase 4 | NCT01963754 Comparator | Apr 2017 → Aug 2023 | local anesthetic poisoning | Implantology Institute | Unknown | No outcome recorded |
| Phase 4 | NCT01951820 Background | Aug 2013 → Jun 2014 | — | University of Michigan | Completed | No outcome recorded |
| Phase 4 | NCT01862614 Comparator | Apr 2013 → May 2014 | — | Ohio State University | Completed | No outcome recorded |
| Phase 4 | NCT01536717 Comparator | Mar 2012 → Dec 2022 | aortic valve disorder, atrial septal defect, mitral valve disorder, myxoma | Helsinki University Central Hospital | Suspended | No outcome recorded |
| Phase 4 | NCT01496846 Comparator | Sep 2011 → Feb 2016 | pulpitis | University of Michigan | Completed | No outcome recorded |
| Phase 4 | NCT01350050 Comparator | Sep → Dec 2009 | — | Helsinki University Central Hospital | Completed | No outcome recorded |
| Phase not applicable12 trials | ||||||
| — | NCT07714915 Comparator | Jul → Aug 2026 overdue | dental pulp disorder | Recep Tayyip Erdogan University Training and Research Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07066306 Comparator | Jun 2025 → Aug 2026 overdue | craniofacial and skeletal defects | Bezmialem Vakif University | Active not recruiting | No outcome recorded |
| — | NCT06927726 Comparator | Jan → Feb 2025 overdue | hypertensive disorder | Tanta University | Enrolling by invitation | No outcome recorded |
| — | NCT06461143 Background | Aug 2024 → Apr 2026 | hypersensitivity reaction disease | Istanbul University | Suspended | No outcome recorded |
| — | NCT05804630 Comparator | Mar 2023 → Jan 2024 | impacted teeth, multiple | National Taiwan University Hospital | Unknown | No outcome recorded |
| — | NCT05531435 Background | Sep 2022 | dental caries, oral sensibility, disturbance of | University of Pavia | Completed | No outcome recorded |
| — | NCT05083975 Background | Jul → Dec 2022 | — | Cairo University | Completed | No outcome recorded |
| — | NCT03443726 Background | Jun 2017 → Nov 2018 | — | University of Barcelona | Completed | No outcome recorded |
| — | NCT03130855 Background | May → Jul 2017 | local anesthetic poisoning | Cairo University | Unknown | No outcome recorded |
| — | NCT02726620 Background | Jan → Dec 2017 | hypotensive disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| — | NCT07018115 Background | Jun 2015 → Feb 2016 | impacted teeth, multiple | Ummugulsum Coskun | Completed | No outcome recorded |
| — | NCT04822415 Comparator | Dec 2014 → Dec 2016 | pulpitis | Cairo University | Completed | No outcome recorded |
Evidence & citations 21 cited values
Every value below carries the sentence it was read from. 82 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Articaine | “Local anesthetic injection of articaine 4% + adrenaline 1/100.000 (Septanest, Septodont, Saint Maur des Fossés, France) with 30G - 9 mm needle (DENTAL HI TEC, ZI de...” NCT05531435 ↗73“The patients were allocated into three different treatment groups to receive 10 ml of either articaine 10 mg/ml, articaine 20 mg/ml, or placebo for gargling and ingestion...” PMID 41949151 ↗ Apr 2026 “Two local anesthetic solutions were compared: the LT group (tramadol and articaine with epinephrine) and the LA group (articaine with epinephrine, control).” PMID 41088090 ↗ Oct 2025 “injections of 3.6 mL of 4% articaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection” NCT02054767 ↗ “Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region at t1.” NCT02246179 ↗ “AG-920 is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%” NCT04759339 ↗ “Orabloc® (1.8mL/cartridge contains 40mg/mL Articaine + 1:100,000 epinephrine)” NCT05804630 ↗ “An inferior alveolar nerve block was given with 4% articaine with epinephrine” NCT05239078 ↗ “or Group A (3.4 ml Articaine hydrochloride 4% with 1:100000 epinephrine)” NCT03725579 ↗ “4% Articaine HCL with 1:1000000 epinephrine Anaesthetic carpule” NCT05473819 ↗ “Articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml” NCT02938286 ↗ “articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml” NCT02548533 ↗ |
| Known as | 40 045 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1093 ↗ |
| Known as | AG-920 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04513652 ↗ |
| Known as | Articaina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1093 ↗ |
| Known as | Articaine chloride | “Articaine chloride 4% with epinephrine” NCT05101785 ↗ |
| Known as | Articaine HCl | “AG-920 is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%” NCT04759339 ↗1“Articaine HCl 4 % / EPINEPHrine 1:100,000 in 1.8 mL Dental Cartridge” NCT05840913 ↗ |
| Known as | articaine hydrochloride | “Buccal infiltrations of 4% articaine (Septanest SP. Articaine hydrochloride 4% with 1:00.000 epinephrine - Septodont, France) will be administered” NCT03880409 ↗15“After pretreatment articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml solution (AHES) will be applied at this test region.” NCT03279757 ↗ “Patients receive either 40 ml of 2% articaine hydrochloride or 40 ml of articaine 2% mixed with dexmedetomidine (1 μg.kg - 1).” PMID 33487824 ↗ Oct 2020 “Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region at t1.” NCT02246179 ↗ “articaine hydrochloride 4% and epinephrine 1:100000 (Septocaine® 1.7ml, SEPTODONT Ltd)” NCT04061265 ↗ “Allocations consisted of 4% Articaine hydrochloride with 1:10000 epinephrine.” PMID 34195402 ↗ Jun 2021 “or Group A (3.4 ml Articaine hydrochloride 4% with 1:100000 epinephrine)” NCT03725579 ↗ “Drug: 1.8 ml of 4% articaine hydrochloride with epinephrine 1:100,000” NCT05083975 ↗ “Articaine Hydrochloride 4 % / Epinephrine 1:200,000 1.8 ML Cartridge” NCT03470532 ↗ “Articaine hydrochloride/epinephrine (adrenaline) hydrochloride” NCT03354312 ↗ “articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml” NCT02548533 ↗ “Articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml” NCT02938286 ↗ “articaine hydrochloride 4% with epinephrine 1:100 000” NCT05944341 ↗ “Drug: Articaine Hydrochloride 40 MG/ML” NCT05252117 ↗ “Articaine hydrochloride 2% solution” NCT01536717 ↗ “1.8 ml articaine hydrochloride BI” NCT05238727 ↗ |
| Known as | Articaine hydrochloride component of orabloc | ChEMBL registry synonym — accepted as the source's own label CHEMBL1093 ↗ |
| Known as | Articaine hydrochloride component of septocaine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1093 ↗ |
| Known as | Artinibsa | “Articaine in a 4% solution with epinephrine 1:100,000 (Artinibsa; Inibsa Dental, Lliçà de Vall, Spain)” NCT03443726 ↗ |
| Known as | Carticaine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1093 ↗ |
| Known as | Carticaine hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL1093 ↗ |
| Known as | HOE 045 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1093 ↗ |
| Known as | HOE-40045 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1093 ↗ |
| Known as | Septanest | ChEMBL registry synonym — accepted as the source's own label CHEMBL1093 ↗ |
| Known as | Septanest SP | “Buccal infiltrations of 4% articaine (Septanest SP. Articaine hydrochloride 4% with 1:00.000 epinephrine - Septodont, France) will be administered” NCT03880409 ↗ |
| Known as | Septocaine | “1.5 ml of 4% articaine with 1:100,000 adrenaline (Septocaine, Septodont, New Castle, Del.)” NCT06980363 ↗1“articaine hydrochloride 4% and epinephrine 1:100000 (Septocaine® 1.7ml, SEPTODONT Ltd)” NCT04061265 ↗ |
| Known as | Ubistesine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1093 ↗ |
| Known as | Ultracain | ChEMBL registry synonym — accepted as the source's own label CHEMBL1093 ↗ |
| Modality | Other / unclassified | “Articaine is an amide-type local anesthetics” NCT01536717 ↗ |
| Route | Intrathecal | “spinal administration of articaine” NCT00247741 ↗ |